Antiasthmatic 151767-02-1 Montelukast Sodium Powder Montelukast Sodium

• Customization: Available
• CAS No.: 151767-02-1
• Formula: C35h35clnnao3s
• Model NO.: QS-Montelukast sodium
• EINECS: 604-813-7
• Packaging Material: Negotiable
• Storage Method: Normal
• Shelf Life: 2 Years
• Nutrient Composition: Montelukast Sodium
• Resource: Montelukast Sodium
• The content of active substances: 99%
• Product Name: Montelukast Sodium
• Name: Montelukast Sodium Powder
• Assay: HPLC 99%
• Appearance: White Powder
• Color: White
• Mf: C35h35clnnao3s
• MW: 558.64
• Melting Point: 84.90
• Boiling Point: 750.5
• Density: 1.272
• Test Method: HPLC
• Grade: Pharmaceutical Grade
• Application: Pharmaceutical
• Specific: COA
• Logp: 7.61330
• Transport Package: Negotiable
• Specification: 99%
• Trademark: QS
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Antiasthmatic 151767-02-1 Montelukast Sodium Powder Montelukast Sodium

Product Description

Product Detials

Product Name	Montelukast sodium
Apperance	White powder
CAS	151767-02-1
MF	C35H35ClNNaO3S
MW	608.17

Montelukast sodium is a Class A medical insurance drug. Adverse reactions: The general tolerance of this drug is good, and the side effects are relatively mild. Usually, treatment does not need to be discontinued. The overall incidence of side effects using this drug was similar to that of the placebo. Clinical studies have evaluated the application of this drug in 2,600 adult patients aged 15 and above. In two 12-week clinical trials with similar designs and placebo as the control, ≥1% of patients in the treatment group of this drug experienced drug-related abdominal pain and headache. Its incidence rate was higher than that of patients who received placebo treatment. However, there was no significant difference in the incidence of the above side effects between the two groups of patients. 544 patients accumulated the use of this drug for at least 6 months in the clinical trial, 253 patients used it for one year, and 21 patients used it for up to 2 years. The adverse reactions of long-term medication were no different from the above.

Application&Function

Purpose
It is effective for asthma and allergic rhinitis asthma syndrome, seasonal allergic rhinitis and perennial allergic rhinitis. The FDA has approved the drug for the treatment of asthma, seasonal and perennial allergic rhinitis. And it is approved for use in adults and children aged 6 months and above.

Specification

Certificate of Analysis